Immunosurveillance von Tumoren und tumorinduzierte Immunsuppression

Ausgewählte weiterführende Literatur:
– Boon T et al., Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12:337–65

– Dougan M, Dranoff G, Immune therapy for cancer. Annu Rev Immunol 2009; 27:83–117

– Rabinovich GA et al., Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267–96

– Hodi FS et al., Improved survival with ipilimumab in patients with metastatic melanoma. NEJM 2010; 363:711-23

– Robert C et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. NEJM 2011; 364:2517–26

– Hamid O et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. NEJM 2013; 369:134–44

– Wolchok JD et al., Nivolumab plus ipilimumab in advanced melanoma. NEJM 2013; 369:122–33

– Schreiber RD et al., Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565–70

– Madan RA et al., Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501–8

– van den Eertwegh AJ et al., Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509–17

– Brahmer JR et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEJM 2012; 366:2455–65

– Topalian SL et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEJM 2012; 366:2443–54

– Hamzah J et al., Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008; 453:410–4

– Curiel TJ, Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167–74